Clinical Trial Update: Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating cediranib maleate with or without dasatinib in hormone-refractory prostate cancer that is resistant to docetaxel has completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-refractory Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Cediranib Maleate (cediranib)
• DASATINIB (Dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hormone Refractory Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-12-05